Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spectrila in adults with newly diagnosed acute lymphoblastic leukemia
RBR-3gz8hcPhase 2Not yet recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
- Start
- Dec 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on RBR-3gz8hc.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3gz8hc.